Background
==========

Colorectal cancer is the third most commonly diagnosed cancer in males and the second in females, with over 1.2 million new cancer cases and 608 700 deaths estimated to have occurred in 2008 \[[@b1-medscimonit-23-4826]\]. Mucinous adenocarcinoma (MAC) is an uncommon and rare histopathological type of colorectal cancer, accounting for 4% to 15% of cases of primary colorectal cancer \[[@b2-medscimonit-23-4826]--[@b4-medscimonit-23-4826]\]. According to the World Health Organization definition, MAC is diagnosed when the extracellular mucin cover 50% of the lesion or more \[[@b5-medscimonit-23-4826]\]. Although rectal cancer is a type of colorectal cancer, the management of rectal cancer is different from that of colon cancer due to its higher postoperative recurrence \[[@b6-medscimonit-23-4826]--[@b8-medscimonit-23-4826]\]. Currently, the standard of care for locally advanced rectal cancer (T3/4 or lymph node-positive) is neoadjuvant chemoradiotherapy (CRT) followed by curative surgery \[[@b9-medscimonit-23-4826],[@b10-medscimonit-23-4826]\]. Although the prognosis of locally advanced rectal cancer has been significantly improved, about 5--10% of these patients develop recurrence \[[@b11-medscimonit-23-4826],[@b12-medscimonit-23-4826]\], and there is marked heterogeneity in the duration of survival among these patients. Therefore, it is necessary to identify patients at greatest risk of worse outcomes by using clinical, inflammatory, and molecular biomarkers.

For the past decade, there has been a growing consensus that inflammation is involved in the development and progression of malignant tumors, including colorectal carcinoma \[[@b13-medscimonit-23-4826]\]. An inflammatory microenvironment promotes the development of tumors by promoting angiogenesis and metastasis, subverting adaptive immune responses, and altering responses to hormones and chemotherapeutic agents \[[@b14-medscimonit-23-4826],[@b15-medscimonit-23-4826]\]. Recently, the markers of systematic inflammatory response, such as neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR), have been reported to be associated with pathological complete response \[[@b16-medscimonit-23-4826]--[@b19-medscimonit-23-4826]\] and prognosis of colorectal cancer \[[@b20-medscimonit-23-4826]--[@b24-medscimonit-23-4826]\]. However, all of these reports included all histopathological types of colorectal cancer, and there have been no reports on the predictive role of systematic inflammatory response in mucinous rectal cancer. The aim of this retrospective study was to evaluate the prognostic significance of pathological and inflammatory markers in mucinous rectal cancer patients receiving neoadjuvant chemoradiotherapy and curative surgery.

Ethics statement
----------------

The Liaoning Cancer Hospital and Institute Ethics Institution Office approved this study. This retrospective study posed no potential risk to the subjects, and the subjects' personal privacy was protected. This study strictly conformed to the principles outlined in the Declaration of Helsinki.

Material and Methods
====================

Patients
--------

The medical records of patients who underwent neoadjuvant chemoradiotherapy and surgical resection at Liaoning Cancer Hospital and Institute from 2006 to 2013 with a diagnosis of mucinous rectal cancer were retrieved from our department. Inclusion criteria were: patients aged 18 years or older with histologically confirmed clinical stage T3/4 or node-positive disease, located within 10 cm of the anal verge, rectal cancer as a single primary tumor, completed neoadjuvant chemoradiotherapy, and received radical surgery.

Clinical variables and definitions
----------------------------------

Data on sex, age at diagnosis, date of diagnosis, pathological diagnosis, neoadjuvant chemotherapy, dose of radiation, time interval from concurrent chemoradiotherapy to operation, preoperative carcinoembryonic antigen (CEA) levels, preoperative α-fetoprotein (AFP) levels, and pathologic features (lymphovascular and perineural invasion) were obtained by reviewing the medical records. All tumors were staged according to the TNM staging system of the American Joint Committee on Cancer (7^th^ version, 2009). Routine laboratory measurements were performed before neoadjuvant chemoradiotherapy. Data on hemoglobin (HB), neutrophil count, lymphocyte count, and platelet count were used to calculate NLR, PLR, and LMR. The cut-off CEA and AFP concentrations were 5.0 and 10 ng/d, respectively, which in our laboratory was the CEA concentration considered abnormal. NLR was defined as a simple ratio of the absolute neutrophil count over lymphocyte count. PLR was defined as the ratio of the platelet count over the absolute lymphocyte count. LMR was defined as the ratio of the absolute lymphocyte count over the monocyte count. Written informed consent was obtained from all patients and the study procedures were approved by the Ethics Committee of Liaoning Cancer Hospital and Institute.

Follow-up
---------

Patients were followed at 3-month intervals for 2 years, at 6-month intervals for the next 3 years, and annually thereafter. The date of last follow-up was March 2016, which was mainly made with telephone calls. Recurrence was determined by clinical and radiologic examination or histologic confirmation. The main pattern of recurrence was recorded as the first site of detectable failure during the follow-up period. Disease-free survival (DFS) was the time from the surgery to the local or distant failure. Overall survival (OS) was calculated from neoadjuvant chemoradiotherapy to death induced by all causes, or end of follow-up.

Statistical analysis
--------------------

Survival analysis was conducted using the Kaplan-Meier method. The comparison of the survival curves was performed by log-rank test. A multivariable Cox regression analysis was performed to identify predictive factors of overall survival. Every variable was analyzed by univariate analysis to cover all potentially important predictors, then variables with *P*≤0.10 in univariate analysis were included in multivariable analysis. This level was chosen to incorporate all potentially important predictor variables in the final modeling process. All sets of variables were analyzed: sex, clinical T stage, clinical N stage, AJCC stage, tumor size, interval from CCRT to operation, total dose of radiation, lymphovascular invasion, perineural invasion, preoperative HB, CEA and AFP levels, and preoperative NLR, PLR, and LMR levels. The optimal cut-off values of NLR, PLR, and LMR were determined by receiver operating characteristic (ROC) analysis, using OS as the end-point. Statistical analysis was performed by using SPSS16.0 software (SPSS Inc., Chicago, IL). *P*\<0.05 was considered statistically significant.

Results
=======

Patient characteristics
-----------------------

The clinical and pathological characteristics of 100 patients (male-to-female ratio: 2.33: 1) are summarized in [Table 1](#t1-medscimonit-23-4826){ref-type="table"}. The median age was 60.5 (26--81 years). The mean preoperative CEA and AFP level was 10.0 U/ml (range 0.48--184 U/ml) and 3.75 U/ml (1.05--22.2), including 18 patients with stage II disease and 82 patients with stage III disease. All patients received intensity-modulated radiation therapy to the pelvis of 45--50 Gy and a concomitant boost of 5 Gy to the primary tumor in 25 fractions. A total of 30 (30%) patients received oral capecitabine alone concurrent with radiotherapy, 65 (65%) patients received both capecitabine and oxaliplatin, and 5 (5%) patients received both oxaliplatin and irinotecan. The median interval between the completion of neoadjuvant chemoradiotherapy and surgery was 7 weeks (range 2--12 weeks) ([Table 1](#t1-medscimonit-23-4826){ref-type="table"}).

The optimal cut-off value for inflammation-based scores
-------------------------------------------------------

ROCs were performed, and the optimal threshold of inflammation-based score was obtained when the Youden index was maximal. The optimal cut-off points of NLR, PLR, and LMR were 2.25 (Youden index, 0.289), 155 (Youden index, 0.257) and 3 (Youden index, 0.371), respectively. Patients were divided into low and high groups based on these cut-off values. In terms of the LMR, 32 (32%) patients had a low LMR and 68 (68%) had a high LMR. For the NLR, 34 patients (34%) were in the low group, whereas 66 (66%) were in the high group. For the PLR, 50 (52%) patients were in the low group, whereas 48 (48%) were in the high group.

Pattern of failure
------------------

After a median follow-up of 45.5 months, a total of 34 mucinous rectal cancer developed recurrence. The specific sites of recurrence were listed in [Table 2](#t2-medscimonit-23-4826){ref-type="table"}. Estimated 5-year DFS rate was 63.3±4.9%. The most common site was lung metastasis (35.3%) and local recurrence (26.5%).

Treatment outcome
-----------------

The median overall survival (OS) for the whole series was 94 months. The estimated 5-year OS rate was 76.8±4.6%. The cumulative 5-year survival was 81.4% for the lymphovascular invasion-positive group and 42.9% for lymphovascular invasion-negative group (*p*=0.005). Additionally, estimated 5-year OS for interval from CCRT to operation more than 7 weeks was also significantly higher than for interval from CCRT to operation less than 7 weeks (82.9% versus 42.9%, *p*=0.023).

Analysis of prognostic factors for overall survival
---------------------------------------------------

On univariate analysis, interval from CCRT to operation ([Figure 1B](#f1-medscimonit-23-4826){ref-type="fig"}), lymphovascular invasion ([Figure 1A](#f1-medscimonit-23-4826){ref-type="fig"}), NLR ([Figure 1C](#f1-medscimonit-23-4826){ref-type="fig"}), and LMR ([Figure 1D](#f1-medscimonit-23-4826){ref-type="fig"}) were significantly predictive for longer survival ([Table 3](#t3-medscimonit-23-4826){ref-type="table"}), whereas sex, tumor size, and T stage were insignificant variables.

In Cox proportional hazard model, pretreatment LMR was found to be an independent prognostic factor for overall survival (hazard ratio, 0.43; 95%*CI*, 0.18 to 1.00, *p*=0.045) ([Table 3](#t3-medscimonit-23-4826){ref-type="table"}).

Discussion
==========

It has been recognized that MAC of the rectum is a rare and distinctive type of cancer. Previous studies demonstrated that mucinous carcinoma is associated with a larger diameter, higher T classification, and extrahepatic localization of metastases \[[@b25-medscimonit-23-4826]--[@b27-medscimonit-23-4826]\], and the prognosis of patients with MAC was worse than that of non-MAC colorectal cancer. Consistent with previous studies, the estimated 5-year DFS and OS rates were 63.3% and 76.8%, respectively. We then analyzed clinical factors or treatment variables that are associated with overall survival in mucinous rectal cancer patients who received neoadjuvant chemoradiotherapy and curative surgery. Our univariate results show that the interval from CCRT to operation (HR 0.37, *p*=0.03), lymphovascular invasion (HR 3.23, *p*=0.009), pretreatment NLR (HR 3.87, *p*=0.012), and LMR (HR 0.31, *p*=0.002) are significant prognostic factors for OS. Multivariate analysis results show pretreatment LMR is an independent prognostic factor for overall survival (hazard ratio, 0.43, *p*=0.045).

The benefit of neoadjuvant chemoradiotherapy in rectal cancer is well established in several phase III trials due to its reduced local recurrence \[[@b28-medscimonit-23-4826],[@b29-medscimonit-23-4826]\], but the best interval between neoadjuvant therapy and surgical treatment is still undetermined. It seems that the radiotherapy-induced necrosis might be time-dependent; thus, a controlled postponement of surgery would allow a potentiation of the effect, maximizing the benefits of neoadjuvant therapy. Francois et al. \[[@b30-medscimonit-23-4826]\] demonstrated that a longer interval between neoadjuvant radiation and surgery was associated with improved tumor clinical response and pathologic downstaging. Recently, Wang et al. performed a meta-analysis and also found that there was a significantly increased rate of pathological complete response in rectal cancer patients treated with surgery followed 7 or 8 weeks later by neoadjuvant chemotherapy (RR, 1.45; 95% CI, 1.18--1.78; and *p*\<0.01 and RR, 1.49; 95% CI, 1.15--1.92; and *p*=0.002, respectively) \[[@b31-medscimonit-23-4826]\]. In the present, we found that estimated 5-year OS for the interval from CCRT to operation more than 7 weeks is significantly higher than for the interval from CCRT to operation less than 7 weeks (82.9% versus 42.9%, *p*=0.023). On univariate analysis, the interval from CCRT to operation is a significant predictor for OS, but it became non-significant in multivariate analysis.

Several previous studies have demonstrated that positive lymphovascular invasion is a predictor of poorer OS in colorectal cancer patients \[[@b26-medscimonit-23-4826],[@b27-medscimonit-23-4826],[@b32-medscimonit-23-4826]\]. Consistent with the published data, we also found that lymphovascular invasion is a significant predictor for OS in mucinous rectal cancer in univariate analysis, but it is not an independent prognostic factor for overall survival in multivariate analysis.

More and more evidence indicates that cancer-related inflammation is involved in cancer development and progression \[[@b33-medscimonit-23-4826],[@b34-medscimonit-23-4826]\]. Neutrophilia, thrombocytosis, monocytosis, and lymphopenia tend to represent a nonspecific response to cancer-related inflammation and are associated with poor survival in cancers \[[@b34-medscimonit-23-4826],[@b35-medscimonit-23-4826]\]. Neutrophils interact with tumor cells by producing cytokines and chemokines, which affects tumor cell proliferation, angiogenesis, and metastases \[[@b36-medscimonit-23-4826]\]. Tumor-associated macrophages, which arise from blood monocytes, promote tumor progression and metastases \[[@b37-medscimonit-23-4826]\]. Chan et al. found that the lymphocyte-to-monocyte ratio was an independent predictor of OS in patients with CRC undergoing curative resection \[[@b23-medscimonit-23-4826]\]. Shibutani et al. \[[@b21-medscimonit-23-4826]\] demonstrated that postoperative NLR was an independent prognostic factor in patients with CRC who underwent potentially curative surgery. However, the prognostic role of inflammatory indexes in mucinous rectal cancer patients who received neoadjuvant chemoradiotherapy and curative surgery remains undetermined. As inflammation-based indexes are simple and comprise components of blood assay with low cost, the establishment of a predictive model based on inflammation is useful, especially for patients in developing countries. In our study, we show that pretreatment NLR and LMR are significant prognostic factors for OS in these patients. Multivariate analysis results show that pretreatment LMR is an independent prognostic factor for overall survival (hazard ratio, 0.43, *p*=0.045).

The main advantage of the present study is that it is one of the largest series evaluating the treatment outcomes of mucinous rectal cancer patients who received neoadjuvant chemoradiotherapy and curative surgery. However, there are several limitations in this study. The major limitation is that it is a retrospective study, which could result in various sources of bias. However, it appears difficult to conduct a randomized trial for this rare disease. Secondly, this is a single-institution study; thus, the findings of this study might not be applicable to other cohorts of patients. Additionally, we evaluated patients who were treated over the course of 7 years. The radiotherapy and chemotherapy regimens may have changed over time.

Conclusions
===========

In conclusion, this large retrospective study demonstrates that pretreatment LMR is an independent clinical predictor for overall survival in patients with mucinous rectal carcinoma treated with neoadjuvant chemoradiotherapy and curative surgery. These findings may help clinicians predict the prognosis of mucinous rectal carcinoma and develop individualized treatment strategies.
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![Univariate analyses for prognostic variable of overall survival: (**A**) Interval from CCRT to operation (\<7 weeks versus ≥7 weeks); (**B**) Lymphovascular invasion (negative versus positive); (**C**) Pretreatment NLR (\<2.25 versus ≥2.25); (**D**) LMR (\<3 versus ≥3).](medscimonit-23-4826-g001){#f1-medscimonit-23-4826}

###### 

Clinicopathologic characteristics of 100 mucinous rectal cancer patients.

  Variable                               Value
  -------------------------------------- -------------------
  Median age (range), y                  60.5 (26--81)
  Gender, n                              
   Male                                  70
   Female                                30
  Tumor size, cm                         
   ≥5                                    9
   \<5                                   91
  T stage, n                             
   T3                                    58
   T4                                    42
  Lymph node involvement, n              
   N(−)                                  19
   N(+)                                  81
  Stage, n                               
   II                                    18
   III                                   82
  Interval from CCRT to operation (wk)   
   \<7                                   64
   ≥7                                    36
  Total dose of radiotherapy (Gy)        
   \<50                                  23
   ≥50                                   77
  Chemotherapy regimens                  
   Capecitabine                          30
   L-OHP+ capecitabine                   65
   CPT-11+capecitabine                   5
  Initial HB                             
   \<10                                  8
   ≥10                                   92
  Preoperative CEA levels                
   Mean (range), U/ml                    10 (0.48--184)
  Preoperative AFP levels                
   Mean (range), U/ml                    3.75 (1.05--22.2)
  Lymphovascular invasion, n             
   Positive                              12
   Negative                              88
  Perineural invasion, n                 
   Positive                              14
   Negative                              86

###### 

Pattern of recurrence.

  Recurrence sites   MAC, n (%)
  ------------------ --------------------------------------------------------
  Total              34[\*](#tfn1-medscimonit-23-4826){ref-type="table-fn"}
  Local recurrence   9
  Liver              7
  Lung               12
  Bone               2
  Lymph node         6

One MAC patient relapsed with lymph node and liver metastasis; another MAC patient relapsed with liver and lung metastasis.

###### 

Predictive factors for overall survival by univariate and multivariate analyses of the cohort (n=100).

  Factors                               Univariate analysis   Multivariate analysis                               
  ------------------------------------- --------------------- ----------------------- ------- ------ ------------ -------
  Gender                                                                                                          
   Female                               1                                                     --                  
   Male                                 1.13                  0.55--2.33              0.74    --     --           --
  T stage                                                                                                         
   T3                                   1                                                     --                  
   T4                                   1.13                  0.55--2.33              0.74    --     --           --
  N stage                                                                                                         
   N(−)                                 1                                                     --                  
   N(+)                                 0.85                  0.36--1.99              0.70    --     --           --
  Stage                                                                                                           
   II                                   1                                                     --                  
   III                                  0.96                  0.39--2.35              0.92    --     --           --
  Preoperative HB level                                                                                           
   \<10                                 1                                                     --                  
   ≥10                                  1.47                  0.35--6.21              0.60    --     --           --
  Tumor size, cm                                                                                                  
   \<5                                  1                                                     --                  
   ≥5                                   1.75                  0.61--5.03              0.30    --     --           --
  Interval from CCRT to operation, wk                                                                             
   \<7                                  1                                                     1                   
   ≥7                                   0.37                  0.15--0.91              0.03    0.49   0.20--1.23   0.13
  Total dose of RT, Gy                                                                                            
   \<50                                 1                                                     --                  
   ≥50                                  0.90                  0.41--1.95              0.79    --     --           --
  Preoperative AFP levels, U/ml                                                                                   
   \<10                                 1                                                     --                  
   ≥10                                  0.91                  0.12--6.72              0.93    --     --           --
  Preoperative CEA levels, U/ml                                                                                   
   \<5                                  1                                                     --                  
   ≥5                                   1.69                  0.81--3.55              0.17    --     --           --
  Lymphovascular invasion                                                                                         
   Negative                             1                                                     1                   
   Positive                             3.23                  1.35--7.75              0.009   2.29   0.92--5.74   0.076
  Perineural invasion                                                                                             
   Negative                             1                                                     --                  
   Positive                             1.68                  0.68--4.12              0.26    --     --           --
  NLR                                                                                                             
   Low (\<2.25)                         1                                                     1                   
   High (≥2.25)                         3.87                  1.35--11.11             0.012   2.87   0.87--9.43   0.082
  PLR                                                                                                             
   Low (\<150)                          1                                                     1                   
   High (≥150)                          2.00                  0.93--4.30              0.074   0.70   0.27--1.80   0.46
  LMR                                                                                                             
   Low (\<3)                            1                                                     1                   
   High (≥3)                            0.31                  0.14--0.64              0.002   0.43   0.18--1.00   0.045
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